Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor Based on extended follow-up of the randomized Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), Dr Doyle and colleagues1 reported that magnesium sulfate given to pregnant women at imminent risk of birth before 30 weeks’ gestation was not associated with neurological outcomes in school-aged children, although they could not exclude a mortality advantage. This report followed a Cochrane meta-analysis of 5 randomized trials including ACTOMgSO4 showing that magnesium sulfate reduced risks of cerebral palsy, general motor dysfunction, and combined death and cerebral palsy by age 2 years in very preterm children.2
Marret S, Bénichou J. Antenatal Magnesium Sulfate and Outcomes for School-aged Children. JAMA. 2015;313(3):306. doi:10.1001/jama.2014.15912
Customize your JAMA Network experience by selecting one or more topics from the list below.